Age-Dependent Cancer Risk Is Not Different in between  MSH2 and MLH1 Mutation Carriers by Olschwang, Sylviane et al.
Hindawi Publishing Corporation
Journal of Cancer Epidemiology
Volume 2009, Article ID 791754, 6 pages
doi:10.1155/2009/791754
Research Article
Age-Dependent Cancer Risk Is not Different in between
MSH2 andMLH1 Mutation Carriers
Sylviane Olschwang,1,2 Kai Yu,3 ChristineLasset,4
St´ ephanie Baert-Desurmont,5 Marie-PierreBuisine,6 Qing Wang,4
PierreHutter,7 EtienneRouleau,8 OlivierCaron,9
ViolaineBourdon,2 and GillesThomas10
1Institut National de la Sant´ ee td el aR e c h e r c h eM ´ edicale (INSERM), Unit´ e 891, Centre de Recherches en Canc´ erologie de Marseille
13009 Marseille, France
2Department of Oncogenetics, Institut Paoli-Calmettes, 13009 Marseille, France
3Division of Cancer Epidemiology and Genetics, National Cancer Institute (NCI), National Institutes of Health (NIH), Gaithersburg,
MD 20877, USA
4Oncogenetics Department, Centre L´ eon B´ erard, 69003 Lyon, France
5Medical Genetics Department, Hˆ opital Charles-Nicolle, 76000 Rouen, France
6Molecular Biology Laboratory, Hˆ opital Claude Huriez, 59000 Lille, France
7Institut Central des H´ epitaux Valaisans, 1951 Sion, Switzerland
8Oncogenetics Department, Centre Ren´ e Huguenin, 92210 Saint-Cloud, France
9Genetics Department, Hospices Civils, 67000 Strasbourg, France
10Fondation Synergie Lyon Cancer, 69008 Lyon, France
Correspondence should be addressed to Sylviane Olschwang, sylviane.olschwang@inserm.fr
Received 22 July 2008; Revised 17 November 2008; Accepted 9 January 2009
Recommended by Thomas L. Vaughan
Lynch syndrome is mostly characterized by early-onset colorectal and endometrial adenocarcinomas. Over 90% of the causal
mutations occur in two mismatch repair genes, MSH2 and MLH1. The aim of this study was to evaluate the age-dependent cancer
riskinMSH2orMLH1mutationcarriersfromdataofDNAdiagnosticlaboratories.Toavoidoverestimation,evaluationwasbased
on the age-dependent proportion of mutation carriers in asymptomatic ﬁrst-degree relatives of identiﬁed mutation carriers. Data
from 859 such eligible relatives were collected from 8 centers; 387 were found to have inherited the mutation from their relatives.
Age-dependent risks were calculated either using a nonparametric approach for four discrete age groups or assuming a modiﬁed
Weibull distribution for the dependence of risk on age. Cancer risk was estimated starting at 28 (25–32 0.68 conﬁdence interval)
and to reach near 0.70 at 70 years. The risks were very similar for MSH2 and MLH1 mutation carriers. Although not statistically
signiﬁcant, the risk in males appeared to precede that for females by ten years. This diﬀerence needs to be investigated on a larger
dataset. If conﬁrmed, this would indicate that the onset of the colonoscopic surveillance may be diﬀerent in male and female
mutation carriers.
Copyright © 2009 Sylviane Olschwang et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Many genetic disorders have been found to exhibit a
simple Mendelian inheritance pattern, and advances in the
knowledgeabouttheirgeneticbasishaveledtotheexpansion
of DNA testing both for diagnosis and prediction of disease
susceptibilities. In the case of mutations associated with
an increased risk of common cancers, one parameter of
major practical importance is the age-dependent cancer risk,
deﬁned as the risk for a mutation carrier of developing a
tumor prior to a given age. Indeed, a precise knowledge of
this parameter is instrumental in the counseling of individu-
als who are identiﬁed as carriers by genetic testing and who
arefacedwithdiﬀerentoptionsforcancerpreventionorearly
detection.
A number of methodologies have been developed to
estimate penetrance and the lifetime risk or recurrence2 Journal of Cancer Epidemiology
risk of cancer prone individuals. Often, the ﬁrst evaluation
of cancer risk is performed from symptomatic individuals
identiﬁed in large pedigrees used in linkage studies [1]. It
has been shown that such design leads to a severe over-
estimation. Alternative evaluation methods, which tend to
reduce such biases, include population-based studies and/or
prospective follow-up of unaﬀected mutation carriers. These
approaches, however, may be expensive, time consuming,
and may require long follow-up in order to provide suﬃcient
information. HNPCC, also known as the Lynch syndrome,
is an autosomal dominant condition caused by mutation
in one or several genes involved in DNA mismatch repair
(MMR) [2]. Mutation carriers have been shown to be at high
risktodevelopcolorectalandendometrialadenocarcinomas.
In addition, signiﬁcantly increased risks have been reported
for cancers of small bowel, upper urological tract, stomach,
ovary, and biliary tract [3]. Although at least four MMR
genes (MSH2, MLH1, MSH6,a n dPMS2) have been impli-
cated in Lynch syndrome, more than 90% of the causative
mutations have been identiﬁed in two of them, MSH2
and MLH1. It has been estimated that the prevalence of
mutationsinthesetwoMMRgenesinthegeneralpopulation
ofEuropean origin is between 1 of 500 and 1 of 1000 [4].The
prevalenceincolorectalcancerpatientsis2.7%[4].Instudies
where ascertainment of Lynch families was not corrected, the
estimated lifetime risk of colorectal cancer ranges from 0.68
to 0.82.
A precise knowledge of the age-dependent risk of cancer
for individuals with deleterious MSH2 and MLH1 mutations
is helpful in the identiﬁcation and clinical management of
families at high risk of colorectal and endometrial cancers.
However,ithasbeenrecognizedthatevaluationofthecancer
risk of HNPCC individuals performed from symptomatic
patientsreferredtoacancerfamilyclinicleadstooverestima-
tion [1, 5, 6]. We had previously brieﬂy delineated an evalua-
tion method which may be less sensitive to recruitment bias.
It is based on the age-dependent proportion of mutation
carriers observed in asymptomatic oﬀspring of mutation
carriers which when applied to 267 individuals led to an
evaluation of the age-dependent risks of ﬁrst cancer to be
approximately 0.43 at age 38 and 0.62 at age 51 in mutation
carriers [7]. The recent development of cancer family clinics
oﬀers the potential to generate a large amount of data,
thus providing the opportunity of improving evaluations of
cancer risk. Here, we more explicitly present the method and
provide an example of its application by studying data from
a total of 859 asymptomatic oﬀspring of mutation carriers,
distributed over an extended range of age, that have been
collected through the contribution of hospital laboratories
which perform genetic testing of MSH2 and MLH1 genes
in France and Switzerland. We also show that the number
of observations has to be substantially increased in order to
provide precise estimates.
2. Patientsand Methods
2.1. Patients. A retrospective questionnaire was sent to eight
genetic units which oﬀer germline analysis of MSH2 and
MLH1 genes under a Health Ministry agreement in France
and Switzerland. This questionnaire asked, for each genetic
test performed on asymptomatic oﬀspring of mutation
carriers, the following information: disease causing germline
mutation identiﬁed in the proband using the international
mutation nomenclature (http://www.hgvs.org/mutnomen/),
birth date, sex, and age at genetic diagnosis. The ques-
tionnaire was fulﬁlled by the biologist having validated the
predictive tests. No follow-up data of the corresponding at-
risk relatives was required.
2.2. Genetic Testing. In all laboratories that provide data,
the presence or absence of the disease causing mutation was
assessed on genomic DNA extracted from two independent
blood samples according to the French and Swiss rules
for examination of the individual genetic characteristics.
Depending on the mutation type, point mutation, or large
genomic rearrangement found in the proband, either by
DNA sequencing or by quantitative, ﬂuorescent multiplex
PCR [8]w a sp e r f o r m e d .
2.3. Risk Calculation. The method is based on the determi-
nation of the age-dependent proportion of mutation carriers
observed in asymptomatic ﬁrst-degree relatives of mutation
carriers at the time of the genetic test. No question about
survival of mutation carrier is addressed in this work. The
probabilities at birth for a ﬁrst-degree relative of a mutation
carrier to be either mutation carrier or nonmutation carrier
are approximately equal and will be assumed equal in the
rest of the study. For these two groups, the proportion of
individuals that become symptomatic with age diﬀers. Let
Πng(t)andΠgc(t)betheprobabilityofanonmutationcarrier
andofamutationcarriertobeaﬀectedbycancerbeforeaget,
respectively. Πgc(t) is also called cancer risk. The proportions
rng and rgc of asymptomatic individuals that can still be
observed at age t are rng = 1 − Πng(t)a n drgc = 1 − Πgc(t).
Therefore, in proportion of mutation carriers at age t in
a group of asymptomatic ﬁrst-degree relatives of mutation
carriers; p(t) = rgc/(rng +rgc), it follows that
πgc(t) =
 
1 − p(t)
  
2 − πng(t)
 
1 − p(t)
. (1)
It is, therefore, possible to evaluate the age-dependent
increased risk of mutation carriers (and, therefore, cancer
risk) from the age-dependent risk of nonmutation carriers
and the age-dependent proportion of mutation carriers
among asymptomatic ﬁrst-degree relatives of mutation car-
riers. In the rest of this work, we will assume that Πng(t)
remains small so that we have the approximate relationship:
Cancer risk = πgc(t) ∼ =
1 −2p(t)
1 − p(t)
. (2)
A nonparametric estimate of the cancer risk can be obtained
as (1 − 2  p(t))/(1 −   p(t)), where   p(t) is an estimation of p(t)
approximated by Nas/(Nng + Nas), where Nas (and Nng)i s
the number of mutation carriers (and noncarriers) sampled
at age between [t − Δt,t + Δt]. Thus, πgc(t) is estimated asJournal of Cancer Epidemiology 3
Table 1: Distribution of mutation carrier and non carrier in 859 unaﬀected individuals with one 1st degree relative carrying a deleterious
MSH2 or MLH1 mutation.
Mutation absent Mutation present
Females Males Females Males
Age group MLH1 MSH2 MLH1 MSH2 MLH1 MSH2 MLH1 MSH2
<30 47 30 52 26 52 38 35 47
30 to 40 36 30 39 28 35 30 25 16
40 to 50 23 25 18 20 18 17 14 10
50 to 60 12 11 20 18 8 10 8 9
> 60 15 10 10 2 7 2 2 4
(Nng −Nas)/Nng, with variance Nas(Nng +Nas)/N3
ng according
to the δ method [9].
A parametric estimate based on the logistic regression
model can also be proposed. Based on the deﬁnition of πgc(t)
and p(t), we have the following important relationship:
log
p(t)
1 − p(t)
= log
 
1 − πgc(t)
 
. (3)
Assuming the following modiﬁed Weibull distribution for
the cancer risk:
πgc(t) =
⎧
⎨
⎩
0, if t ≤ τ,
1 −exp
 
−
 
a(t −τ)
 b 
,i f t>τ ,
(4)
we observe that
log
p(t)
1 − p(t)
= log
 
1 −π(t)
 
=− a
 
(t −τ)
+ b. (5)
This equation suggests the familiar logistic regression model.
We can consider the following simple model:
log
p(t)
1 − p(t)
= β(t −τ)
+. (6)
We can ﬁnd the maximum likelihood estimate of (β,τ)
by maximizing the likelihood function based on the above
probability model. Once we have an estimate for (β,τ),
we can obtain the estimate for πgc(t)f o ra n yg i v e nt.W e
call this estimate the parametric estimate. To obtain the
conﬁdence interval of the parametric estimate, we use the
standard bootstrap method [10]. To compare the cancer risk
between two groups, such as males and females, we used
the likelihood ratio statistic that compares the likelihood
assuming the same parametric model (i.e., the common
(β,τ) for both samples) with the likelihood obtained by
allowing (β,τ) to be varied between two samples. The
statistical signiﬁcance of the test can be evaluated through a
permutation procedure by randomly shuﬄing the group ids
(i.e., gender or gene name) among all subjects.
3. Results
Eight genetic units contributed information on a total of 859
asymptomatic oﬀspring of mutation carriers: 581 from SO,
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Figure 1: Cumulative risk of cancer for MSH2 and MLH1 mutation
carriers. Individuals are not diﬀerentiated with respect to the
mutated gene or gender. The ﬁve horizontal blue lines indicate
the risk for each of the 5 groups as shown in Table 1.F o rt h e
youngest group, the risk was evaluated to zero. For the other four
groups, the vertical line is placed at the median age and indicates
the 0.68 conﬁdence interval for the evaluated risk. The red curve
showstheriskevaluatedassumingthatitfollowsamodiﬁedWeibull
distribution as a function of age. The two ﬂanking dotted graphs
indicate the 0.68 conﬁdence interval of this evaluation. The age at
onset of the risk is evaluated to 28 (0.68 conﬁdence interval = 25–32
years).
116 from CL and QW, 58 from SBS, 44 from MPB, 21 from
PH, 16 from ER, 14 from OC, and 9 from VB. They were 472
nonmutation carriers (233 males and 239 females, aged 18
to 89 years) and 387 mutation carriers. Mutation was located
within the MSH2 gene in 183 cases (86 males and 97 females,
aged 18 to 73 years) and within the MLH1 gene in 204 cases
(84 males and 120 females, aged 18 to 74 years). Mutations
were all predicted to result in protein truncation or were
missense mutations classiﬁed as deleterious on the basis of4 Journal of Cancer Epidemiology
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Figure 2: Cumulative risk of cancer for mutation carriers when individuals are diﬀerentiated with respect to the mutated gene (part (a)) or
gender (part (b)). The risk estimation was only attempted under the assumption that the risk follows a modiﬁed Weibull distribution as a
function of age.
functional tests in yeast, cosegregation analyses, and tumor
cells studies. First-degree relatives of index cases carrying
DNA variants of unknown signiﬁcance were removed from
this study. The 859 unaﬀected ﬁrst-degree relatives of MSH2
and MLH1 mutation carrier were classiﬁed into ﬁve age
groups (Table 1).
When both the gender and the nature of the mutated
gene (whether MSH2 or MLH1) are considered, the number
of observations in each group is too small to enable a non-
parametric evaluation of the cancer risk. Pooling together
the four groups (MHS2, MLH1, males, and females), we
attempted a nonparametric evaluation of the age-dependent
cancer risk. It can be observed that as pooled age groups
become older, the proportions of aﬀected mutation carriers
tendtodecrease.Thisdecreaseisduetotheremovalfromthe
study of the mutation carriers who become symptomatic. In
the younger age group, the number of mutation carriers was
larger than that of the nonmutation carriers, an observation
that is likely due to the small number of observations and
which suggests that cancer risk is very small in this age
group. For the other groups, the proportion of mutation
carriers was smaller than 0.5, and thus for these groups,
a nonzero cancer risk could be estimated (Figure 1). For
instance, for the age group between 50 and 60, the median
age was 53, and the cancer risk was evaluated to 0.43. We
note that the standard deviation of the present evaluation is
large.
In an attempt to obtain a more precise evaluation,
we performed a parametric estimate of the age-dependent
cancer risk assuming that cancer risk would be negligible
before an age threshold called τ, and starting from this
age, cancer risk would increase according to a Weibull
distribution with a parameter β. Weibull distributions are
currently used in survival analyses and have been applied
to parameterize age-dependent cancer risk [11]. Under
this model, the maximum likelihood estimate of τ is 28
years (68% conﬁdence interval 25–32 years). After this age,
cancer risk rises rapidly and reaches a value of 0.48 (68%
conﬁdence interval 0.42–0.54) at 53 years, and 0.67 (68%
conﬁdence interval 0.59–0.74) at 70 years. After this age,
the probability of a nonmutation carrier to have developed
cancer becomes substantial so that the model may need to be
corrected according to (1). The number of observations of
nonsymptomatic ﬁst-degree relatives older than 70 is small
in our series, and no attempt was made to evaluate cancer
risk after this age.
A similar method was applied separately on asymp-
tomatic individuals with ﬁrst-degree relatives carrying an
MLH1 or an MHS2 mutation. The diﬀerence is risk for
MSH2 and MLH1 mutation carriers appeared minimal
(Figure 2(a)). When males and females were analyzed sep-
arately, the age-dependent risk for males appeared shifted
by ten years as compared to females. Under the parametric
model, the age at onset of the increased risk in males is
23 years (95% conﬁdence interval 11–27) as it is 32 years
(95% conﬁdence interval 29–37) in females. However, a
permutation test failed to demonstrate statistical signiﬁcance
(P = .15).Journal of Cancer Epidemiology 5
4. Discussion
There is a clear need to improve our estimation of the age-
dependent cancer risk for many genetic diseases. This is
especially important for those conditions that predispose
to cancer as this knowledge may inﬂuence the deﬁnition
of the best surveillance protocol. The development of
presymptomatic DNA diagnostic tests oﬀers an opportunity
to improve this knowledge. However, we need to apply
methods that are less prone to biases than those based on
the age at the onset of symptomatic individuals referred to
cancer family clinics [11, 12].
The evaluation method discussed in this paper requires
a set of data that are collected in a two-stage process. In the
ﬁrst stage, symptomatic individuals are referred to a clinic
andthedeleteriousmutationsareidentiﬁed.Importantly,the
age at onset of the symptomatic individuals collected at this
stage is not used to evaluate cancer risk as it is well known
that such procedure may lead to major overestimation.
In the second stage, asymptomatic ﬁrst-degree relatives of
individuals with an identiﬁed mutation are recruited and a
test is conducted to determine their mutation status. Cancer
risk is only evaluated from the age-dependent proportion
of gene carriers in this group of asymptomatic ﬁrst degree
relatives. This method shares some of the potential biases
that may be observed in population-based studies. The
highly penetrant mutations are likely to contribute more
than the low-penetrant mutations as the earlier are more
readily detected than the former. Also mutations that lie in
chromosomal regions that are investigated by routine DNA
diagnostic techniques (e.g., mainly exonic point mutations
or genomic large rearrangements) have been preferentially
included in the study. Thus, the group of mutations that
havebeenevaluatedforcancerriskmaynotberepresentative
of the mutation spectrum that is present in the population.
However, for the group of mutations that have been identi-
ﬁed, the method appears minimally biased. This lack of bias
stems from the requirement that the individuals included in
the study should be asymptomatic.
The present method requires a large number of observa-
tions. With the present dataset, variance of our estimation
is large. It is barely informative when a nonparametric
evaluation method is used (e.g., when individuals are pooled
into 10-year age groups). The assumption of a modiﬁed
Weibull distribution for cancer risk enables to decrease
this variance at the cost of minimal hypotheses. Simulation
studies indicate that the collection of a 4-fold increased
the number of observations would decrease the conﬁdence
interval by a factor 2 (results not shown). With the develop-
ment of presymptomatic DNA diagnostic tests, such number
should be obtainable in the near future at little cost.
In the present work, we have applied the method to the
evaluation of the age-dependent cancer risk of mutations in
theMSH2andMLH1genesassociatedwithLynchsyndrome.
The resulting evaluation of the age-dependent cancer risk is
consistent with those that have been previously published
based on population-based studies [13]. It does conﬁrm
that the previous evaluation based on the age at onset
of retrospectively included symptomatic individuals was
overestimated. It also indicates that as previously proposed,
cancer risk of MLH1 and MSH2 mutations is similar [14].
An analysis distinguishing gender also suggests that the onset
of the increased risk occurs ten years earlier in males than
in females. This observation, if conﬁrmed, suggests that the
colonoscopy surveillance in males may have to be started
earlier than in females, possibly leading to changes in the
standard guidelines [15, 16]. Also, if it is conﬁrmed that
cancer risk is lower at all ages in females than in males, it
would imply that the colorectal risk may be much smaller in
females that in males since females are also at high risk of
endometrial cancer. Similar observations have been recently
published in the literature [12, 14].
Besides Lynch syndrome, it would be of interest to apply
this approach to predisposing diseases for which the ﬁrst
manifestations are not present at birth and which may have
irreversible deleterious consequences when the diagnosis
is delayed until symptomatic. This includes not only the
cancer predisposing conditions such as those associated
to BRCA mutations [17, 18] but also possibly conditions
associatedwithotherdegenerativeprocesses(neurologicalor
metabolic).
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